To the editors:
In March 2013, a novel influenza A H7N9 virus of avian origin was reported to cause severe pneumonia in mainland China [1] [2] [3] . While the great majority of patients were treated with oral oseltamivir, impaired gastrointestinal absorption in critically ill patients, the lack of virological response among patients requiring extracorporeal membrane oxygenation (ECMO), and detection of the an amino acid change (arginine to lysine at residue 292, N2 numbering) in the viral neuraminidase associated with drug resistance in two H7N9 strains are major concerns [1, 4] . Here, we report a case of severe pneumonia due to avian influenza A H7N9 requiring ECMO support and there was rapid clinical and virological response following intravenous zanamivir therapy.
On 21 November 2013, a 36-year-old Indonesian female in Hong Kong began to have fever, malaise, and cough. She had been previously healthy except for a history of vitiligo.
She sought medical advice from two clinics and was given symptomatic treatment. She attended the accident and emergency department of a regional hospital in Hong Kong on 27
November when the symptoms deteriorated. Her temperature was 40.0 o C, blood pressure was 120/63 mmHg, pulse was 116 beats•min -1 , respiratory rate was 18 breaths•min -1 and oxygenation was 97% while breathing ambient air. A chest radiograph showed right lower zone consolidation.
After admission, there was persistent fever and rapid progression of the radiological infiltrates to both lungs and development of parapneumonic effusion despite treatment with intravenous amoxicillin-clavulanate, ceftriaxone, azithromycin, and oral oseltamivir (75 mg twice daily, total two doses given). Endotracheal intubation and mechanical ventilation were required on 29 November. Desaturation worsened and she was put on ECMO on 30
November. Initial microbiological workup including sputum culture, blood culture, urine for legionella and pneumococcal antigens, two nasopharyngeal swabs for influenza A and B
antigens, and tracheal aspirate for human metapneumovirus, Mycoplasma pneumoniae, Chlamydophila pneumoniae and Mycobacterium tuberculosis by PCR were negative.
In view of the rapid disease progression, the respiratory specimens were subjected to testing for avian influenza viruses [5] . PCR identified presence of H7N9 in all the respiratory specimens (throat swab, nasopharyngeal swabs and aspirates, tracheal aspirate, and pleural fluid) collected since hospitalization. No H7N9 was detected in urine and rectal swabs. PCR for influenza A subtypes H1, H3 and H5 of the nasopharyngeal swabs and tracheal aspirates was negative. Therapy with intravenous zanamivir 600 mg every 12-hourly was started on 2
December. Quantitative PCR targeting the matrix gene demonstrated that the viral loads had declined rapidly following zanamivir therapy (Figure) . Sequence analysis of the neuraminidase gene of the virus recovered from tracheal aspirate showed no resistance associated mutations. Patient's condition improved clinically and she was extubated after 2 days and ECMO was discontinued on 6 December. Subsequently, it was revealed that patient had a history of buying, slaughtering, and eating a chicken in Shenzhen on 17 November.
Here, we document, for the first time, rapid virological clearance in a patient with severe H7N9 pneumonia requiring ECMO. In the absence of comparative clinical studies, the optimal antiviral therapy for pneumonia caused by H7N9 remains uncertain. Genetic analysis and in vitro susceptibility testing demonstrated that most strains of H7N9 are susceptible to neuraminidase inhibitors oseltamivir and zanamivir, but resistant to adamantanes [1] . In patients with respiratory failure, inhalational neuraminidase inhibitors are unlikely to be helpful because the drugs are not expected to reach the consolidated lungs. For hospitalized patients with suspected or confirmed H7N9 influenza, both oral oseltamivir and intravenous zanamivir are currently considered to be acceptable alternatives for therapy [6, 7] . Although enterically administered oseltamivir is well absorbed in critically ill influenza patients, intravenous zanamivir is preferred for patients with gastric stasis, malabsorption or gastrointestinal bleeding [6] . Antiviral therapy in the present patient was switched to intravenous zanamivir because a study by Hu et al found that patients on ECMO responded poorly to enterically administered oseltamivir and that neuraminidase-resistant mutants may emerge during oseltamivir therapy under such clinical circumstances [4] . In accordance with previous observations, decline in viral loads in our patient correlated with clinical improvement [1, 4] . Our findings are useful for informing choice of antiviral therapy in future 
